Search
Talacotuzumab
go.drugbank.com/drugs/DB14796InvestigationalTalacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.
AMY-101
go.drugbank.com/drugs/DB14803InvestigationalAMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3.
Pegcrisantaspase
go.drugbank.com/drugs/DB16281InvestigationalPegcrisantaspase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young
Siagoside
go.drugbank.com/drugs/DB12351InvestigationalSiagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.
Toyocamycin
go.drugbank.com/drugs/DB13916ExperimentalIt is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.
INO-4800
go.drugbank.com/drugs/DB15693Investigational(NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … [L14372] A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.[L14375]
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Prinomastat
go.drugbank.com/drugs/DB05100InvestigationalAs a lipophilic agent, prinomastat crosses the blood-brain barrier.